PNC Financial Services Group
BCRX icon

PNC Financial Services Group’s BioCryst Pharmaceuticals BCRX Stock Holding History

PNC Financial Services Group’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$218K Buy
21,832
+4,457
+26% +$40.3K ﹤0.01% 2400
2026
Q1 		$165K Sell
17,375
-340
-2% -$2.64K ﹤0.01% 2459
2025
Q4 		$138K Buy
17,715
+800
+5% +$5.78K ﹤0.01% 2576
2025
Q3 		$128K Buy
16,915
+1,349
+9% +$11.2K ﹤0.01% 2632
2025
Q2 		$139K Sell
15,566
-333
-2% -$3.1K ﹤0.01% 2467
2025
Q1 		$119K Sell
15,899
-1,337
-8% -$10.8K ﹤0.01% 2550
2024
Q4 		$130K Sell
17,236
-997
-5% -$7.57K ﹤0.01% 2506
2024
Q3 		$139K Buy
18,233
+349
+2% +$2.65K ﹤0.01% 2461
2024
Q2 		$111K Buy
17,884
+424
+2% +$2.34K ﹤0.01% 2568
2024
Q1 		$88.7K Buy
17,460
+6,533
+60% +$36.7K ﹤0.01% 2677
2023
Q4 		$65.5K Sell
10,927
-990
-8% -$5.74K ﹤0.01% 2831
2023
Q3 		$84.4K Sell
11,917
-6,018
-34% -$43.2K ﹤0.01% 2674
2023
Q2 		$126K Buy
17,935
+2,688
+18% +$21.6K ﹤0.01% 2497
2023
Q1 		$127K Buy
15,247
+3,027
+25% +$29.1K ﹤0.01% 2419
2022
Q4 		$140K Buy
12,220
+2,520
+26% +$31.4K ﹤0.01% 2354
2022
Q3 		$122K Buy
9,700
+4,917
+103% +$63.3K ﹤0.01% 2398
2022
Q2 		$51K Buy
4,783
+1,111
+30% +$11.5K ﹤0.01% 2979
2022
Q1 		$59K Sell
3,672
-1,506
-29% -$24.2K ﹤0.01% 3002
2021
Q4 		$71K Buy
5,178
+5,089
+5,718% +$67.3K ﹤0.01% 2897
2021
Q3 		$1K Hold
89
– – ﹤0.01% 4173
2021
Q2 		$1K Hold
89
– – ﹤0.01% 4092
2021
Q1 		$1K Buy
+89
New +$918 ﹤0.01% 4012
2018
Q1 		– Sell
-103
Closed -$1K – 4174
2017
Q4 		$1K Buy
+103
New +$499 ﹤0.01% 4072
2016
Q3 		– Sell
-301
Closed -$1K – 3989
2016
Q2 		$1K Sell
301
-12
-4% -$37 ﹤0.01% 4334
2016
Q1 		$1K Buy
313
+198
+172% +$878 ﹤0.01% 4345
2015
Q4 		$1K Buy
+115
New +$1.14K ﹤0.01% 4307

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

PNC Financial Services Group's BCRX Position: Q2 2026 in Review

PNC Financial Services Group increased its BioCryst Pharmaceuticals (BCRX) stake by 26% in Q2 2026, buying an estimated $40.3K and bringing the position to 21,832 shares worth $218K. The position accounts for ﹤0.01% of the portfolio, ranked #2400.

PNC Financial Services Group first reported a position in BCRX in Q4 2015 and has held it in 26 quarters since. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • PNC Financial Services Group held 21,832 shares of BioCryst Pharmaceuticals worth $218K as of Q2 2026.
  • PNC Financial Services Group bought 4,457 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $40.3K.
  • BioCryst Pharmaceuticals made up ﹤0.01% of PNC Financial Services Group's portfolio in Q2 2026, its #2400 holding.
  • PNC Financial Services Group first reported a position in BioCryst Pharmaceuticals in Q4 2015 and has held it in 26 quarters since.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on PNC Financial Services Group's 13F filing for Q2 2026, filed 7 Aug 2026.